Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2020 Earnings Conference Call February 22, 2021 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Emad Samad - Octaviant Ed Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full year 2020 Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be opened for your questions following the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (previously known as Cytori Therapeutics, Inc.) (Exact name of Registrant as Specified in Its Charter) ...

Corporate Presentation January 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this document that is not a historical fact is a "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may ...

Financial Data and Key Metrics Changes - As of September 30, 2020, cash and cash equivalents decreased to $7.6 million from $17.6 million as of December 31, 2019 [12] - The company reported no revenues in Q3 2020, down from $4.8 million in the same period last year, attributed to the closeout of BARDA contracts [12] - Net loss for Q3 2020 was $1.7 million, compared to a net income of $0.5 million in Q3 2019, primarily due to a $7 million loss from discontinued operations in 2019 [16] Business Line Data and Key Metrics Changes - Research and development expenses were $0.3 million in Q3 2020, down from $0.9 million in Q3 2019, with a total of $1.6 million for the nine months ended September 2020 compared to $3.6 million in the same period in 2019 [13] - Sales and marketing expenses remained approximately $0.1 million in Q3 2020, unchanged from the previous year [14] - General and administrative expenses were $1 million for Q3 2020, unchanged from the same period last year, while for the nine months ended September 30, 2020, G&A was $3.8 million compared to $3.3 million in 2019 [15] Market Data and Key Metrics Changes - The FDA granted Orphan designation and Fast Track designation for RNL for the treatment of patients with recurrent glioblastoma during Q3 2020 [8] Company Strategy and Development Direction - The company is focused on advancing the development of RNL, with plans to complete enrollment in the ReSPECT trial by year-end 2020 and to report updated dataset enrollment progress at the Society for Neuro-Oncology meeting in mid-November [18] - The company is exploring additional clinical development programs for RNL, including indications such as leptomeningeal carcinomatosis, peritoneal carcinomatosis, and recurrent head and neck cancer [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the enrollment pace for Cohort 6 of the ReSPECT trial, citing corporate resources and partnerships with institutions like NCI as factors contributing to accelerated progress [32] - The company is awaiting specifics on potential funding opportunities from the state Cancer Fund, which could support RNL's development for additional indications [33] Other Important Information - The company announced the formation of a Clinical Advisory Board to support the development of RNL, consisting of experts in neurosurgery and neuro-oncology [7] - The company is actively manufacturing the drug for ReSPECT and is working on proper manufacturing controls and capabilities for late-stage clinical trials [19] Q&A Session Summary Question: Will overall survival data be provided at the upcoming meeting? - Yes, overall survival data will be provided, but it will include patients who have been recently treated and still alive, making it a blend of data [22] Question: Are alternative trial approaches being considered for RNL's registration study? - Yes, the company is considering synthetic controls and other trial approaches in discussions with the FDA, given the lack of approved treatments in the recurrent setting for nearly a decade [24] Question: What is the timeline for Cohort 6 enrollment? - Enrollment for Cohort 6 is expected to be similar to previous cohorts, with an accelerating pace due to corporate resources and additional sites being onboarded [32] Question: Is there an update on funding from the state Cancer Fund? - The company is awaiting specifics on a potential RFP for funding, which could support RNL for recurrent glioblastoma and other indications [33] Question: Will the company produce all drugs in-house for future studies? - The company plans to manufacture the drug in-house but may outsource some work due to the unique nature of the drug and supply chain logistics [40]

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q2 2020 Earnings Conference Call August 10, 2020 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Robert LeBoyer - Ladenburg Thalmann Ed Woo - Ascendiant Capital Emad Samad - WBB Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Second Quarter 2020 Earnings Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your qu ...

Financial Data and Key Metrics Changes - The operating cash burn for Q1 2020 was approximately $1.5 million, a decrease from $3.3 million in Q1 2019, primarily due to discontinued operations and reduced operating expenses [27] - The net loss for Q1 2020 was $1.1 million, compared to a net loss of $3.2 million in Q1 2019, attributed to discontinued operations and changes in fair value of warrants [27] - Total revenues for Q1 2020 were $0.1 million, down from $0.7 million in Q1 2019, mainly due to the closeout of a government contract with BARDA [28] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses in Q1 2020 were $0.9 million, down from $1.4 million in Q1 2019, due to decreased spending following the sale of the former Cell Therapy business [27] - Sales and marketing expenses remained consistent at approximately $0.1 million [28] - General and administrative (G&A) expenses increased to $1.5 million in Q1 2020 from $1.4 million in Q1 2019, driven by increased professional fees [28] Market Data and Key Metrics Changes - As of March 31, 2020, the company had $16.1 million in cash and $9.3 million in debt principal, with total liabilities at $20.8 million, down from $22 million at the end of 2019 [29] Company Strategy and Development Direction - The company aims to optimize the regulatory and clinical program for RNL for glioblastoma and plans to expand the Phase 1 trial from one to three sites [32] - The strategic focus includes leveraging non-dilutive funding sources and exploring additional indications for RNL, such as head and neck cancer and leptomeningeal carcinomatosis [41][42] - The company is committed to a disciplined approach in assessing new pipeline enhancement opportunities while focusing resources on RNL development [26][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position, noting that there have been no significant supply chain interruptions and no material impact on results for fiscal year 2020 due to COVID-19 [7][29] - The company is optimistic about the potential of the newly licensed RNL technology to redefine treatment for brain cancer and other poorly met cancer indications [10][12] Other Important Information - The company received a modest PPP loan approval but chose not to participate, citing its ability to operate normally during the pandemic [8] - The company donated personal protective equipment to frontline healthcare workers during the pandemic [9] Q&A Session Summary Question: Can you provide details on the Phase 1 trial enrollment? - The company has enrolled 13 patients so far and is currently treating the first patient in the fifth cohort, with plans to enroll between six to eight patients per cohort [36] Question: What outcomes are being measured in the Phase 2 trial? - The focus will be on survival as an outcome, with potential for exploring surrogate endpoints to expedite the clinical path [37] Question: Are there discussions with the FDA regarding fast track or orphan designation? - The company has not yet communicated with the FDA but considers it a priority to explore these designations [38] Question: What other indications are being considered for RNL? - Potential indications include head and neck cancer and leptomeningeal carcinomatosis, with ongoing analysis to determine the most promising opportunities [40][41] Question: Will the company focus on multiple indications simultaneously? - The company anticipates focusing on at least one additional indication, depending on capital availability and agency requirements [43] Question: Is the funding for RNL through the National Cancer Institute already secured? - Yes, the funding has been awarded and will be disbursed over time as the project progresses [46][47] Question: What is the current status of partnerships for DoxoPLUS and DocePLUS? - The company is seeking partnerships but has not yet found the right deal, focusing resources primarily on the RNL program [48] Question: How is the company's cash position for future operations? - The company has approximately 12 to 18 months of cash balance without raising additional capital, depending on the speed of RNL development [51]

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2019 Results Conference Call March 30, 2020 5:00 PM ET Company Participants Dr. Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Ed Woo - Ascendiant Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Fourth Quarter and Full Year 2019 Earnings Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for questions following the presentation. [Operator Inst ...

Delivering More For Patients Positively Impacting Healthcare Marc Hedrick, MD President & CEO Nasdaq: PSTV Biotech Showcase January 14, 2020 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on our management's current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. All statements, other than stat ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2019 Earnings Conference Call November 14, 2019 5:00 PM ET Company Participants Dr. Marc Hedrick - President and Chief Executive Officer Desiree Smith - Corporate Controller and Principal Accounting Officer Conference Call Participants Emad Samad - WBB Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics Investor Conference Call. At this time, all participants have been placed in a listen-only mode and the floor will be open for questions f ...

Cytori Therapeutics, Inc. (CYTX) Q4 2018 Results Earnings Conference Call April 1, 2019 8:30 AM ET Company Participants Marc Hedrick - President and Chief Executive Officer Tiago Girão - Chief Financial Officer, Outgoing Gary Titus - Chief Financial Officer, Incoming Conference Call Participants Jason McCarthy - Maxim Group Yale Jen - Laidlaw & Company Operator Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Fourth Quarter and Full Year 2018 Earnings Results Call. At this time, all ...